PT2062573E - Sistemas transdérmicos que contêm opióides que resistem a violação - Google Patents

Sistemas transdérmicos que contêm opióides que resistem a violação Download PDF

Info

Publication number
PT2062573E
PT2062573E PT08020810T PT08020810T PT2062573E PT 2062573 E PT2062573 E PT 2062573E PT 08020810 T PT08020810 T PT 08020810T PT 08020810 T PT08020810 T PT 08020810T PT 2062573 E PT2062573 E PT 2062573E
Authority
PT
Portugal
Prior art keywords
component
microspheres
transdermal
dosage form
solvent
Prior art date
Application number
PT08020810T
Other languages
English (en)
Portuguese (pt)
Inventor
Benjamin Oshlack
Bruce E Reidenberg
James P Cassidy
Richard S Sackler
Lino Tavares
Curtis Wright
Anthony E Carpanzano
Rampurna Prasad Gullapalli
Ihor Shevchuk
Mark A Alfonso
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of PT2062573E publication Critical patent/PT2062573E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
    • B09B2101/00—Type of solid waste
    • B09B2101/65—Medical waste
    • B09B2101/68—Transdermal patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT08020810T 2001-05-01 2002-04-30 Sistemas transdérmicos que contêm opióides que resistem a violação PT2062573E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28787501P 2001-05-01 2001-05-01
US29253701P 2001-05-22 2001-05-22

Publications (1)

Publication Number Publication Date
PT2062573E true PT2062573E (pt) 2012-01-11

Family

ID=26964697

Family Applications (3)

Application Number Title Priority Date Filing Date
PT08020810T PT2062573E (pt) 2001-05-01 2002-04-30 Sistemas transdérmicos que contêm opióides que resistem a violação
PT100099431T PT2316439E (pt) 2001-05-01 2002-04-30 Sistemas transdérmicos resistentes a violação que contêm opióides
PT02731653T PT1397095E (pt) 2001-05-01 2002-04-30 Sistemas transdérmicos que contêm opióides resistentes a violação

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT100099431T PT2316439E (pt) 2001-05-01 2002-04-30 Sistemas transdérmicos resistentes a violação que contêm opióides
PT02731653T PT1397095E (pt) 2001-05-01 2002-04-30 Sistemas transdérmicos que contêm opióides resistentes a violação

Country Status (11)

Country Link
US (2) US20040241218A1 (2)
EP (3) EP2062573B1 (2)
JP (3) JP5296284B2 (2)
AT (2) ATE533478T1 (2)
CY (2) CY1108821T1 (2)
DE (1) DE60230138D1 (2)
DK (3) DK2062573T3 (2)
ES (3) ES2318010T3 (2)
PT (3) PT2062573E (2)
SI (3) SI2062573T1 (2)
WO (1) WO2002087482A1 (2)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
AU2002339378A1 (en) 2001-05-22 2002-12-03 Euro-Celtique Compartmentalized dosage form
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
JP2005526839A (ja) * 2002-04-23 2005-09-08 アルザ・コーポレーシヨン 不正使用の可能性が低い経皮鎮痛薬システム
ES2283812T3 (es) * 2002-06-10 2007-11-01 Euro Celtique Sa Sistemas de eliminacion de dispositivos de adminsitracion transdemica para prevenir el uso indebido de los agentes activos contenidos en los mismos.
US7815934B2 (en) * 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
DE10250088A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
RS20050812A (sr) * 2003-04-30 2007-12-31 Purdue Pharma L.P., Transdermalni dozni oblik otporan na promene
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
DE602004011055T2 (de) * 2003-07-25 2008-12-18 Euro-Celtique S.A. Präoperative behandlung von postoperativen schmerzen
CA2543610A1 (en) * 2003-10-30 2005-05-19 Alza Corporation Transdermal analgesic systems having reduced abuse potential
US8535711B2 (en) 2004-01-23 2013-09-17 Teikoku Pharma Usa, Inc. Medication disposal system
US7867511B2 (en) 2004-01-23 2011-01-11 Travanti Pharma Inc. Abuse potential reduction in abusable substance dosage form
PT1718258E (pt) * 2004-02-23 2009-06-16 Euro Celtique Sa Dispositivo de administração transdérmica de opióides com resistência ao abuso
WO2006023644A2 (en) * 2004-08-20 2006-03-02 3M Innovative Properties Company Transdermal drug delivery device with translucent protective film
US7226619B1 (en) 2004-09-07 2007-06-05 Pharmorx Inc. Material for controlling diversion of medications
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
SI1814531T1 (sl) * 2004-10-21 2010-10-29 Durect Corp Transdermalni dostavni sistem
WO2006069008A1 (en) * 2004-12-22 2006-06-29 Vesta Medical, Llc Compositions and devices for inactivation of pharmaceuticals to facilitate waste disposal, and methods thereof
US20060182819A1 (en) * 2005-02-17 2006-08-17 Ough Yon D Soap scent patch and treatment for muscle spasm and pain
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
EP1898891A2 (en) * 2005-05-13 2008-03-19 Alza Corporation Multilayer drug delivery system with barrier against antagonist exposure
ATE478659T1 (de) 2005-05-13 2010-09-15 Alza Corp Mehrlagiges arzneimittelausbringsystem mit sperre gegen reservoirmaterialfluss
US20070014839A1 (en) * 2005-07-18 2007-01-18 Stefan Bracht Decomposer film for transdermal patches
US9056061B2 (en) 2005-09-23 2015-06-16 Alza Corporation Transdermal nicotine salt delivery system
US8383149B2 (en) 2005-09-23 2013-02-26 Alza Corporation High enhancer-loading polyacrylate formulation for transdermal applications
EP1968539A2 (en) * 2005-12-13 2008-09-17 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
DE102006025282A1 (de) * 2006-05-31 2007-12-20 Lts Lohmann Therapie-Systeme Ag Selbstzerstörendes transdermales therapeutisches System
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
US20080008747A1 (en) * 2006-07-07 2008-01-10 Royds Robert B Transdermal patch
DK2054031T3 (en) 2006-07-21 2016-05-17 Biodelivery Sciences Int Inc Transmucosal delivery devices with improved uptake
WO2008063301A2 (en) * 2006-10-11 2008-05-29 Alpharma, Inc. Pharmaceutical compositions
US20080286348A1 (en) * 2007-05-16 2008-11-20 Todhunter John A Secured transdermal delivery system
DE102007041557B4 (de) * 2007-08-29 2011-03-31 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend längliche Hohlkörper
US20090196890A1 (en) * 2007-12-17 2009-08-06 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
JP2011515495A (ja) * 2008-03-26 2011-05-19 オールトランツ インコーポレイティド オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑制経皮製剤
DE102008016804B4 (de) * 2008-04-02 2012-01-05 Lts Lohmann Therapie-Systeme Ag Selbstzerstörendes transdermales therapeutisches System mit verbesserter Funktionalität und Wirksamkeit sowie seine Verwendung
JP2013523780A (ja) * 2010-04-02 2013-06-17 オールトランツ インコーポレイティド オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑止性経皮製剤
WO2013006643A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
AU2012296346A1 (en) 2011-08-18 2014-04-03 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
WO2013049380A1 (en) 2011-09-30 2013-04-04 Teikoku Pharma Usa, Inc. Transdermal patch disposal system
JP2014528276A (ja) 2011-09-30 2014-10-27 テイコク ファーマ ユーエスエー インコーポレーテッド 一般用医薬品廃棄システム
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
WO2016049266A1 (en) * 2014-09-24 2016-03-31 Pain Therapeutics, Inc. 4:3 naltrexone: 5-methyl-2-furaldehyde cocrystal
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
WO2017147568A1 (en) * 2016-02-26 2017-08-31 Case Western Reserve University Composite membranes for flow batteries
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US11389844B2 (en) 2018-03-20 2022-07-19 Verde Environmental Technologies, Inc. Blister pack disposal system
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
WO2020008366A1 (en) * 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal dosage form
WO2020009685A1 (en) * 2018-07-02 2020-01-09 John Tang Transdermal dosage form
US20210346662A1 (en) * 2018-10-23 2021-11-11 Kindeva Drug Delivery L.P. Tamper evident transdermal patch
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
CN114401746A (zh) * 2019-08-12 2022-04-26 耶路撒冷希伯来大学伊森姆研究发展有限公司 包括鸦片拮抗剂组合的药学组合物及复合材料及其使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3643987A1 (de) * 1986-12-22 1988-06-23 Lohmann Therapie Syst Lts Basische, wirkstoffdurchlaessige haftklebende polymermasse, insbesondere zum einsatz mit basischen wirkstoffen, verfahren zu ihrer herstellung und ihre verwendung
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5028435A (en) * 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5573778A (en) * 1995-03-17 1996-11-12 Adhesives Research, Inc. Drug flux enhancer-tolerant pressure sensitive adhesive composition
WO1997004835A1 (de) * 1995-07-28 1997-02-13 Novartis Ag Transdermales system
US7011843B2 (en) * 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
CA2314896C (en) * 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
US6554851B1 (en) * 1999-05-07 2003-04-29 Scimed Life Systems, Inc. Methods of sealing an injection site
EP1424973B1 (en) * 2001-04-23 2010-03-03 Euro-Celtique S.A. Disposal system for transdermal dosage form

Also Published As

Publication number Publication date
EP1397095A4 (en) 2005-05-25
EP2316439A1 (en) 2011-05-04
ES2318010T3 (es) 2009-05-01
EP1397095A1 (en) 2004-03-17
DE60230138D1 (de) 2009-01-15
EP1397095B1 (en) 2008-12-03
EP2062573A1 (en) 2009-05-27
JP2004529155A (ja) 2004-09-24
DK1397095T3 (da) 2009-03-09
DK2316439T3 (en) 2015-08-10
SI2062573T1 (sl) 2012-02-29
US20140199383A1 (en) 2014-07-17
US20040241218A1 (en) 2004-12-02
ATE415952T1 (de) 2008-12-15
PT1397095E (pt) 2009-02-17
EP2316439B1 (en) 2015-06-17
PT2316439E (pt) 2015-08-28
JP2013144702A (ja) 2013-07-25
CY1108821T1 (el) 2014-04-09
ES2546828T3 (es) 2015-09-29
EP2062573B1 (en) 2011-11-16
JP5296284B2 (ja) 2013-09-25
JP2015042649A (ja) 2015-03-05
SI2316439T1 (sl) 2015-10-30
DK2062573T3 (da) 2012-01-30
WO2002087482A1 (en) 2002-11-07
ES2377672T3 (es) 2012-03-29
CY1112271T1 (el) 2015-12-09
ATE533478T1 (de) 2011-12-15
SI1397095T1 (sl) 2009-04-30

Similar Documents

Publication Publication Date Title
PT2062573E (pt) Sistemas transdérmicos que contêm opióides que resistem a violação
Malick et al. Analgesic activity of substance P following intracerebral administration in rats
Mendes et al. Assessment of mechanisms involved in antinociception caused by sesquiterpene polygodial
CA2250010C (en) Denaturants for sympathomimetic amine salts
AU2004261182B2 (en) Treatment of dependence withdrawal
EP2004147B1 (en) Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive
Pol et al. Diarrhea associated with intestinal inflammation increases the potency of mu and delta opioids on the inhibition of gastrointestinal transit in mice.
US20050191340A1 (en) Opioid-receptor antagonists in transdermal systems having buprenorphine
CN114949220A (zh) 一种靶向损伤节段背根神经节的pH响应镇痛药及其应用
Jain et al. Brain drug delivery system bearing dopamine hydrochloride for effective management of parkinsonism
Chesher et al. The quasi-morphine withdrawal syndrome: effect of cannabinol, cannabidiol and tetrahydrocannabinol
AU2021334058A1 (en) Mucosa perforation
US20040126417A1 (en) Transdermal buprenorphine to treat pain in sickle cell crisis
Fakhry et al. Formulation and evaluation of diphenhydramine HCL release from different semi-solid bases (cream, gel and ointment)
CN1723902A (zh) 一种恩诺沙星微囊及制备方法
KR20130142990A (ko) 오피오이드의 설하 전달용 약제 조성물
KR20200106503A (ko) 가교결합된 이온 교환 수지를 함유하는 약학적 조성물
Konstantinopol'skiĭ et al. The withdrawal syndrome and lipid peroxidation during the chronic administration of narcotic analgesics to rats
TW219330B (2)
Watanabe et al. Possible interaction of endomorphins with antineoplastic agents in human monocytic leukemia THP-1
CN102160857A (zh) 哌甲酯贴剂
US20130216603A1 (en) Pharmaceutical compositions and delivery devices comprising stinging cells or capsules
Kovatsi et al. New trends in drug abuse coming from USA
KR20200117999A (ko) 수지 입자를 함유하는 약학적 조성물